Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.78 |
| ▸ | NSD2 | O96028 | 3/20 | 0.71 |
| ▸ | SETD2 | Q9BYW2 | 2/20 | 0.71 |
| ▸ | PLA2G7 | Q13093 | 9/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17209750 | 1.00 | SMYD3 (0.78) | SMYD3NSD2SETD2PLA2G7HRH4 | |
| SCHEMBL17209755 | 1.00 | SMYD3 (0.78) | SMYD3NSD2SETD2PLA2G7HRH4 | |
| SCHEMBL25038007 | 0.89 | SMYD3 (0.76) | SMYD3NSD2SETD2PLA2G7HRH4 | |
| SCHEMBL26098907 | 0.89 | SMYD3 (0.80) | SMYD3NSD2SETD2PLA2G7HRH4 | |
| SCHEMBL25040319 | 0.89 | SMYD3 (0.80) | SMYD3NSD2SETD2PLA2G7HRH4 | |
| SCHEMBL25037859 | 0.89 | SMYD3 (0.80) | SMYD3NSD2SETD2PLA2G7HRH4 | |
| SCHEMBL26097606 | 0.89 | SMYD3 (0.80) | SMYD3NSD2SETD2PLA2G7HRH4 | |
| SCHEMBL25040197 | 0.88 | SMYD3 (0.74) | SMYD3NSD2SETD2PLA2G7HRH4 | |
| SCHEMBL21489812 | 0.88 | SMYD3 (1.00) | SMYD3NSD2SETD2PLA2G7HRH4 | |
| SCHEMBL19710050 | 0.88 | SMYD3 (1.00) | SMYD3NSD2SETD2PLA2G7HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. | 2024-09-12 | — | — | US | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230049113-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | Epizyme, Inc. | 2023-02-16 | — | — | US | disclosed |
| WO-2022261243-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2020112872-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | Epizyme, Inc. (US) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020037079-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | SETD2, CARM1, SETDB1 | SMYD3 386/4885NSD2 35/4885SETD2 1/4885 |
| US-20230049113-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | NSD1, NSD3, EHMT1 | SMYD3 31/4885NSD2 6/4885SETD2 8/4885 |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | EZH2, HDAC2, SETD2 | SMYD3 489/4885NSD2 14/4885SETD2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.